Stock market reports show that Allergan and Medicis, makers of popular wrinkle treatments Botox and Dysport, increased their profits this year beyond projections.
Analysts have partially attributed the growth to sales of the cosmetic treatments.
Wall Street Journal reports that a 3 percent increase in Botox sales helped Allergan’s third quarter profit rise 8.3 percent, with new medical uses of Botox on the horizon that could drive sales even further.
Dysport, the new kid on the block, apparently hasn’t managed to put a dent in Allergan’s sales, but it certainly seems to be helping Medicis make a profit. Revenues for the Dysport manufacturer last quarter were up 31 percent from the same period last year, according to CNN Money. Medicis CEO Jonah Shacknai says, “We are encouraged by the positive physician and patient response to DYSPORT.”
There aren’t an overwhelming number of people asking for Dysport in San Francisco, but Botox continues to attract patients to our office. The brand awareness of Botox is hard to beat, and that probably won’t change anytime soon.
Tags: botox
